WO2012111996A2 - 갈란타민 또는 그의 염을 함유하는 경피흡수제제 - Google Patents
갈란타민 또는 그의 염을 함유하는 경피흡수제제 Download PDFInfo
- Publication number
- WO2012111996A2 WO2012111996A2 PCT/KR2012/001186 KR2012001186W WO2012111996A2 WO 2012111996 A2 WO2012111996 A2 WO 2012111996A2 KR 2012001186 W KR2012001186 W KR 2012001186W WO 2012111996 A2 WO2012111996 A2 WO 2012111996A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug
- galantamine
- permeation
- matrix layer
- containing matrix
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
Definitions
- the present invention relates to a transdermal absorbent preparation comprising galantamine or a salt thereof as an active ingredient, and more particularly, a drug-containing matrix formed using a styrene-butadiene-styrene copolymer or a styrene-isoprene-styrene copolymer as an adhesive.
- a transdermal absorption preparation comprising a matrix layer.
- Alzheimer's Jalhwan is the most common form of dementia.
- Alzheimer's disease is a neurological disorder characterized by loss of mental capacity, which severely interferes with the normal activities of daily life. Alzheimer's disease usually occurs in the elderly, with deterioration of cognitive functions such as memory, reasoning, and planning.
- the average survival time of onset patients are known to be about 8-year from onset of symptoms (Coyle, J., Kershaw, P. , 2001. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors:. Effects on the course of Alzheimers disease Biol Psychiatry . 49, 289-299).
- Galantamine (galantamine) is a tertiary alkaloid, is a reversible and competitive acetylcholine S. atmospheres inhibitor (Zarotsky, V., Sramek, JJ, Cutler, NR, 2001. Galantamine hydrobromide:.. An agent for Alzheimer's disease Am J Health- Syst.Pharm . 60, 446-452). Galantamine is very effective for the treatment of symptoms of Alzheimer's disease and improves the patient's cognition, global function, and daily living ability (Scott, LJ, Goa, KL, 2000. Galantamine: a review of its use) in Alzheimer's disease.Drugs . 60, 1095-1122; Corey-Bloom, J., 2003. Galantamine: a review of its use in Alzheimer's disease and vascular dementia.Int . J. Clin. Pract. 57, 219-223).
- galantamine is commercially available as a tablet or oral solution. Oral administration of galantamine has side effects such as abdominal pain, nausea and diarrhea. Thus, other methods of administering galantamine may help in the treatment success.
- Transdermal drug delivery systems have the advantage of reducing gastrointestinal side effects such as nausea and nausea, which are the most common side effects that lead to discontinuation of treatment.
- TDDS provides advantages such as providing sustained and regulated plasma drug concentrations, enhancing bioavailability, and avoiding first-pass metabolism.
- their use is often limited due to the outermost layer of the skin, ie the stratum corneum.
- stratum corneum is only 20-25 ⁇ m thick, it provides a strong barrier to the penetration of many compounds and poses an important problem for therapeutic TDDS (Thomas, BJ, Finnin, FC, 2004. The transdermal revolution. Drug Discov. Today, 9, 697-703. Walters, KA, Walker, M., Olejnik, O., 1987.Non-ionic surfactant effects on hairless mouse skin permeability characteristics.J. Pharm.Pharmacol . 40, 525-529 ).
- TDDS TDDS
- a pressure sensitive adhesive PSA
- adheresive is a skin Not only performs adhesion function against, but also acts as the foundation of the formulation.
- the tack characteristics must also be considered before selecting an appropriate tack.
- U.S. Patent 5,700,480 discloses a transdermal absorbent comprising a drug-containing layer containing galantamine, a plasticizer, and a polyacrylate (e.g., an acrylate copolymer / methacrylate copolymer) as an adhesive. I've done it.
- Transdermal absorption preparations according to US Pat. No. 5,700,480 show low permeability of about 2.7 ⁇ g / cm 2 / hr.
- US Patent Publication No. 2007 / 0104771A1 discloses an acrylate polymer having a polar funtional monomer component, at least 10% by weight galantamine, and 4.5 ⁇ g.
- a transdermal absorption preparation including a drug-containing layer containing a permeation accelerator capable of delivering galantamine with a permeability of / cm 2 / hr or more has been disclosed.
- the permeability of the transdermal absorbent preparation according to US Patent Publication No. 2007 / 0104771A1 is 11.35 ⁇ g / cm 2 / hr (Table 2), which still has a low permeability problem.
- the present invention provides a transdermal absorption agent comprising galantamine or a salt thereof, which can stably maintain a therapeutically effective blood concentration for at least 24 hours and can provide high skin permeability by preventing crystallization of galantamine or a salt thereof. to provide.
- an object of the present invention is to provide a transdermal absorption preparation containing galantamine or a pharmaceutically acceptable salt thereof, which stably exhibits high skin permeability for 24 hours or more.
- galantamine or a pharmaceutically acceptable salt thereof as an active ingredient A transdermal absorbent comprising a drug-containing matrix layer comprising a styrene-butadiene-styrene copolymer or a styrene-isoprene-styrene copolymer as an adhesive is provided.
- the transdermal absorption agent may be composed of a support layer, a drug-containing matrix layer, and a release layer.
- the galantamine or a pharmaceutically acceptable salt thereof may be contained in the range of 0.5 to 20% by weight, preferably 10 to 20% by weight, based on the total weight of the drug-containing matrix layer.
- the content of the pressure-sensitive adhesive may be in the range of 70 to 95% by weight based on the total weight of the drug-containing matrix layer.
- Transdermal absorption preparations are propylene glycol laurate, lauryl alcohol, triacetin, isopropyl myristate, cinemaol, polyoxyethylene lauryl ether, oleoyl macrogol glycerides, and caprylocaproyl macrogol glycerol It may further comprise a permeation promoter selected from the group consisting of a ride.
- the permeation accelerator may preferably use polyoxyethylene lauryl ether, and the content of the permeation promoter may be in the range of 0.5 to 10 wt%, preferably about 5 wt%, based on the total weight of the drug-containing matrix layer.
- the thickness of the drug-containing matrix layer may be in the range of 50 ⁇ m to 100 ⁇ m, preferably in the range of 50 ⁇ m to 80 ⁇ m.
- the transdermal absorbent preparation according to the present invention is composed of a styrene-butadiene-styrene copolymer or a styrene-isoprene-styrene copolymer as a pressure-sensitive adhesive, thereby preventing the crystallization of galantamine or its salts in the matrix layer, thereby providing a therapeutic effect. This can maintain a stable blood concentration for at least 24 hours.
- transdermal absorption preparations according to the invention can achieve high skin permeability of up to 38 ⁇ g / cm 2 / hr.
- the present invention provides galantamine or a pharmaceutically acceptable salt thereof as an active ingredient;
- a transdermal absorbent comprising a drug-containing matrix layer comprising a styrene-butadiene-styrene copolymer or a styrene-isoprene-styrene copolymer as an adhesive.
- the present inventors conducted various studies on adhesive properties, drug concentration, matrix layer thickness, permeation accelerator, and the like to improve the low skin permeability of a transdermal absorbent using a conventional acrylic adhesive.
- the inventors have found that the low permeability of galantamine is caused by the interaction of the carboxyl functional groups of the adhesive with the tertiary amine groups of galantamine; It has also been found that it is caused by crystallization of galantamine in a matrix using an acrylic pressure sensitive adhesive.
- the present inventors design a drug matrix layer using a specific adhesive, ie, styrene-butadiene-styrene copolymer or styrene-isoprene-styrene copolymer. It has been found that galantamine-adhesive interactions and crystallization of galantamine can be effectively prevented and stable high skin permeability can be achieved.
- the pressure-sensitive adhesive that is, styrene-butadiene-styrene copolymer or styrene-isoprene-styrene copolymer performs an adhesive function and also forms a drug base (foundation or base), the content of which is not particularly limited, but 70 to 95 weight It may be in the range of%, preferably in the range of 80 to 90% by weight.
- the galantamine or a pharmaceutically acceptable salt thereof may be used in an amount sufficient to obtain a therapeutically effective blood concentration, For example in the range of 0.5 to 20% by weight, preferably in the range of 10 to 20% by weight, more preferably in the range of 10 to 15% by weight and particularly preferably in the range of about 15% by weight relative to the total weight of the drug-containing matrix layer. It may be contained. If the content of galantamine or a pharmaceutically acceptable salt thereof is less than 0.5% by weight, the area of transdermal absorption agent for the therapeutic effect of the drug may be enlarged more than necessary to decrease the patient's compliance. In addition, when the content of galantamine or a pharmaceutically acceptable salt thereof exceeds 20% by weight, crystals of the drug may be formed in the drug-containing matrix layer, thereby reducing adhesion or decreasing the drug transmittance.
- a therapeutically effective blood concentration For example in the range of 0.5 to 20% by weight, preferably in the range of 10 to 20% by weight, more preferably in the range of 10 to 15% by weight and particularly
- the transdermal absorption agent according to the present invention may include a permeation accelerator, the content of the permeation accelerator is different depending on the type of permeation accelerator used, 0.5 to 10 relative to the total weight of the drug-containing matrix layer Range by weight, preferably about 5 Weight percent. If the content of the permeation promoter is less than 0.5% by weight, the permeation promoting effect may be insignificant. In addition, when the content of the permeation accelerator is more than 10% by weight, the permeation promoting effect may not be very high. If too much permeation accelerator is used, cold flow may occur due to poor adhesion to the skin or weakening cohesion.
- the permeation enhancer is propylene glycol monolaurate (propyleneglycol laurate) [e.g., lauroyl glycol ® FCC (Lauraglycol ® FCC)] , lauryl alcohol (lauryl alchol), triacetin (triacetin), isopropyl myristate (isopropyl myristate ), Cineole, polyoxyethylene lauryl ether (e.g.
- Brij TM 30, Brij TM 52, etc. oleoyl macrogol glyceride (or polyethylene glycol- 8 glyceryl Li fun eth- (PEG-8 glyceryl linoleate)) [ e.g., LabrafilTM ® 2609 CS (Labrafil ® 2609), etc.], and the cap-reel caproyl macrogol glyceride (caprylocaproyl macrogol glycerides) (or polyethylene -8 glycol glyceryl caprylate / caprate (PEG-8 glyceryl caprylate / caprate )) [ for instance, in case of bras Sol ® (Labrasol ®), etc.] may be at least one selected from the group consisting of. Of these, polyoxyethylene lauryl ether can be preferably used as the permeation promoter.
- the thickness of the drug-containing matrix layer may be in the range of 50 ⁇ m to 100 ⁇ m, preferably in the range of 50 ⁇ m to 80 ⁇ m.
- about 80 ⁇ m thick drug-containing consisting of about 15 wt% galantamine, about 5 wt% polyoxyethylene lauryl ether, and the balance consisting of styrene-butadiene-styrene copolymer
- a transdermal absorbent preparation comprising a matrix layer is provided.
- the transdermal absorbent preparation of the present invention may be composed of a support layer, a drug-containing matrix layer, and a release layer.
- the transdermal absorbent preparation of the present invention composed of the support layer, the drug-containing matrix layer, and the release layer can be prepared by forming the above-described drug-containing matrix layer on the release layer and again forming the support layer thereon.
- the release layer may be a release liner or a laminate thereof commonly used in the field of transdermal absorbents, for example, polyethylene, polyester, polyvinyl chloride, polyvinylidene coated with silicone resin or fluorine resin. Films such as chloride, paper or laminates thereof can be used.
- the support layer (also referred to as a backing membrane) can also be used a drug-non-absorbing and flexible material commonly used in the field of transdermal absorbents, for example, polyolefin, polyether ( polyether, multi-layer ethylene vinyl acetate film, polyester, polyurethane, and the like may be used.
- the transdermal absorption preparations of the present invention dissolve galantamine or a pharmaceutically acceptable salt thereof in a suitable solvent (e.g., chloroform, etc.), and are used in styrene-butadiene-styrene copolymer or styrene-isoprene-styrene air. After mixing the coalescence (and the permeation promoter as necessary), the obtained mixture can be prepared by, for example, applying a silicone coated paper and dried, followed by laminating a support layer.
- a suitable solvent e.g., chloroform, etc.
- Lauroyl glycol ® FCC (Lauraglycol ® FCC)] , lauryl alcohol (lauryl alchol), triacetin (triacetin), isopropyl myristate (isopropyl myristate), the cine ol (cineole), polyoxyethylene lauryl ether (polyoxyethylene lauryl ether) (e.g., Brij TM 30, Brij TM 52, etc.), oleoyl macrogol glycerides (oleoyl macrogol glyceride) [e.g., LabrafilTM ® 2609 CS (Labrafil ® 2609), etc.], and as caprylic caproyl macrogol glyceride (caprylocaproyl macrogol glycerides) [for instance, in case of bras Sol ® (Labrasol ®), etc.]
- lauryl alcohol lauryl alchol
- triacetin triacetin
- isopropyl myristate iso
- Galantamine was purchased from Ivax Pharmaceuticals (Opava- Komarot, Czech Republic).
- Polyethyleneglycol-8 glyceryl caprylate / caprate PEG-8 glyceryl caprylate / caprate
- Labrasol ® Polyethylene glycol-8 glyceryl linoleate
- Oleic acid, propylene glycol and sorbitan monooleate (Span ® 80) were purchased from Junsei Chemical (Tokyo, Japan).
- Isopropyl myristate (IPM) and PEG-20 almond glyceride (Crovol ® A40) were purchased from Croda (Parsippany, NJ, USA). Cineol, lauryl alcohol and Brij ® 30 were purchased from Sigma Chemical (St. Louis, MO, USA).
- Acrylic adhesive solution, polyisobutylene (PIB) adhesive solution and SBS adhesive solution in organic solvents were obtained from National Starch and Chemical Company (Bridgewater, NJ, USA).
- Silicone adhesive solution (BioPSA ® 7-4302) was obtained from Dow Corning (Midland, MI, USA). All other chemicals were above reagent grade and used without further purification.
- Galantamine was dissolved in chloroform and then mixed with a permeation accelerator and an adhesive. The resulting mixture was cast on a release liner. After standing at room temperature for 10 minutes, the mixture was dried at 80 ° C. for 20 minutes to remove residual organic solvent. After evaporation of the solvent, it was laminated as a dry film, the polyester support film (backing film) (ScotchPak ® 9728 , 3M, USA).
- Galantamine was slightly modified using the reported method (Ang, C., Fen, HE, Sub, HE, 2006. Pharmacokinetics of galantamine Hbr in plasma and brain of mice.Chin . J. Pharm . 37, 55-61). Modified and analyzed. Using an HPLC system (Shimadzu Scientific Instruments, MD) consisting of a UV detector (SPD-10A), a C18 column (4.6 ⁇ 100 mm, 5 ⁇ m, Gemini), a pump (LC-10AD), and an autoinjector (SIL-10A) It was. The wavelength of the UV detector was 230 nm, the column temperature was maintained at 30 ° C., the flow rate was 1 mL / min, and the injection volume was 30 ⁇ L. The mobile phase consisted of methanol / water (35/65, v / v) containing 0.2% triethylamine and adjusted to pH 6.4 with phosphoric acid.
- Permeation data were obtained from methods developed for flow-through diffusion systems (Choi, HK., Angello, J., 1994. The Mathematical analysis and optimization of a flow through diffusion cell system.Pharm . Res. 11, 595-599). Analyzed by.
- the selection of a suitable adhesive matrix is very important for designing TDDS.
- the physicochemical properties of the adhesive can greatly affect the skin penetration of the drug (Subedi, RK, Jang, JH, Kim, Jae-II, Park, YJ, Choi, H.-K., 2010. Formulation and evaluation of transdermal patch containing sibutramine.J. Kor. Pharm. Sci. 40, 33-38).
- the influence of the adhesive matrix on the permeation of galantamine was evaluated using an acrylic matrix, an acrylic rubber hybrid matrix, an SBS matrix, a silicone matrix, and a PIB matrix. Physical and chemical properties of each pressure-sensitive adhesive is shown in Table 1 below.
- the thickness of the matrix layer is one of the important parameters in the development of matrix-type TDDS.
- the thicker the matrix the greater the amount of drug delivered to the skin during relatively long application times (Furuishi, T., Io, T., Fukami, T., Suzuki, T., Tomono, K., 2008. and in vitro evaluation of pentazocine transdermal drug delivery system.B iol. Pharm. Bull. 31 , 1439-1443). This is because higher amounts of drug can be penetrated from the patch.
- thicker matrices are known to have a higher tendency to cause cold flow (Wokovich, AM, Prodduturi, S., Doub, WH, Hussain, AS, Buhse, LF, 2006.
- Transdermal drug delivery system (TDDS) ) adhesion as a critical safety, efficacy and quality attribute.Eur . J. Pharm. Biopharm . 64, 1-8). Therefore, the effect of thickness on patches loaded with galantamine was tested to evaluate the permeation and adhesion properties. In the 24-hour study, it was not possible to distinguish permeation properties from matrices of various thicknesses. In long-term tests up to 48 hours, the thick adhesive matrix showed better and more consistent profiles (see FIG. 6). In particular, the thin matrix (40 ⁇ m) exhibited a decrease in transmission. The sticking properties of the prepared patches were evaluated by thumb tack test. As a result, it was found that the matrix thickness of 50 ⁇ m or more had sufficient adhesive force.
- TDDS Transdermal drug delivery system
- the permeation did not increase significantly, and the profiles obtained were nearly similar.
- thicker matrix thicknesses may cause undesirable cold flow, which may be undesirable, and considering the adhesion and potential cold flow, the matrix thickness is preferably between 50 ⁇ m and 80 ⁇ m, with about 80 ⁇ m being It is considered to be the most desirable.
- Permeation accelerators serve to reversibly lower the permeation barrier of the stratum corneum.
- the permeation promoter can also act as a plasticizer to increase the mobility of the drug in the matrix.
- Permeation rate Permeation rate using permeation accelerator / permeation rate without using permeation accelerator
- chroman view ® A40 propylene glycol, polyethylene glycol (PEG) 400, trans kyutol ® and glycerol did not promote the permeation of galantamine.
- lauroglycol ® FCC lauryl alcohol, triacetin, isopropyl myristate (IPM), cineol, breeze ® 30, labrafil ® 2609, and labrasol ® significantly increased the penetration of galantamine. Increased. Of these, Breeze ® 30 and lauroglycol ® FCC showed a relatively high increase for galantamine.
- Breeze ® 30 showing the highest growth rate, was used at different concentrations (2.5-10% v / w per polymer weight) to assess the effect on galvantamine's skin permeation at 15% w / w drug loading.
- the increase in permeation of galantamine was observed to increase with the increase of the permeation promoter (see FIG. 7).
- the level of Breeze ® 30 was increased from 2.5% v / w to 5% v / w, a significant increase in permeation was observed. However, the increase in permeation was not very pronounced when the concentration of Breeze ® 30 exceeded 5% v / w.
- an optimized formulation ie about 15% by weight galantamine, about 5% by weight polyoxyethylene lauryl ether, and the balance consisting of styrene-butadiene-styrene copolymer, about 80 ⁇ m thick drug-containing Transdermal absorption formulations comprising a matrix layer can provide a permeability of 38 ⁇ g / cm 2 / h, which is expected to deliver 8 mg galantamine daily, even with small patch sizes of less than 9 cm 2 .
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
상표명 | 화학적 조성 | 관능기 |
Durotak® 87-2510 | 아크릴레이트(Acrylate) | OH |
Durotak® 87-504 A | 아크릴 고무 하이브리드(Acrylate rubber hybrid) | OH |
Durotak® 87-2979 | 아크릴 비닐 아세테이트(Acrylate vinyl acetate) | OH/COOH |
Durotak® 87-9301 | 아크릴 공중합체(Acrylate copolymer) | 비-관능성(Non functional) |
SBS 6174 | 열가소성 고무 블럭 공중합체(Thermoplastic rubber block copolymer) | 비-관능성(Non functional) |
BIO-PSA® 7-4302 | 실록산(Siloxane) | 비-관능성(Non functional) |
PIB 10711-62 | 폴리이소부틸렌(Polyisobutylene) | 비-관능성(Non functional) |
투과촉진제 | 투과촉진율* |
대조군 | 1.00 ± 0.00 |
라우릴 알코올(Lauryl alcohol) | 1.28 ± 0.10 |
라브라필(Labrafil)® 2609 | 1.28 ± 0.03 |
라브라솔(Labrasol)® | 1.16 ± 0.07 |
폴리에틸렌 글리콜(Propylene glycol) | 0.76 ± 0.06 |
스판(Span)® 80 | 1.09 ± 0.07 |
크로볼(Crovol)® A40 | 0.98 ± 0.02 |
이소프로필 미리스테이트(IPM) | 1.26 ± 0.14 |
PEG 400 | 0.92 ± 0.01 |
브리즈(Brij)® 30 | 1.68 ± 0.08 |
시네올(Cineole) | 1.12 ± 0.03 |
트리아세틴(Triacetin) | 1.19 ± 0.01 |
글리세린(Glycerin) | 0.86 ± 0.01 |
라우로글리콜(Lauroglycol)® FCC | 1.59 ± 0.04 |
트랜스큐톨(Transcutol)® | 0.80 ± 0.02 |
Claims (11)
- 유효성분으로서 갈란타민 또는 그의 약학적으로 허용가능한 염; 점착제로서 스티렌-부타디엔-스티렌 공중합체 또는 스티렌-이소프렌-스티렌 공중합체를 포함하는 약물-함유 매트릭스층을 포함하는 경피흡수제제.
- 제1항에 있어서, 상기 경피흡수제제가 지지층, 약물-함유 매트릭스층, 및 박리층으로 구성된 것을 특징으로 하는 경피흡수제제.
- 제1항에 있어서, 상기 갈란타민 또는 그의 약학적으로 허용가능한 염의 함량이 약물-함유 매트릭스층 총 중량에 대하여 0.5∼20 중량%의 범위인 것을 특징으로 하는 경피흡수제제.
- 제1항에 있어서, 상기 갈란타민 또는 그의 약학적으로 허용가능한 염의 함량이 약물-함유 매트릭스층 총 중량에 대하여 10∼20 중량%의 범위인 것을 특징으로 하는 경피흡수제제.
- 제1항에 있어서, 상기 점착제의 함량이 약물-함유 매트릭스층 총 중량에 대하여 70∼95 중량%의 범위인 것을 특징으로 하는 경피흡수제제.
- 제1항 내지 제5항 중 어느 한 항에 있어서, 프로필렌글리콜 라우레이트, 라우릴 알코올, 트리아세틴, 이소프로필 미리스테이트, 시네올, 폴리옥시에틸렌 라우릴 에테르, 올레오일 마크로골 글리세라이드, 및 카프릴로카프로일 마크로골 글리세라이드로 이루어진 군으로부터 1 종 이상 선택된 투과촉진제를 추가로 포함하는 것을 특징으로 하는 경피흡수제제.
- 제6항에 있어서, 상기 투과촉진제가 폴리옥시에틸렌 라우릴 에테르인 것을 특징으로 하는 경피흡수제제.
- 제6항에 있어서, 상기 투과촉진제의 함량이 약물-함유 매트릭스층 총 중량에 대하여 0.5∼10 중량%의 범위인 것을 특징으로 하는 경피흡수제제.
- 제6항에 있어서, 상기 투과촉진제의 함량이 약물-함유 매트릭스층 총 중량에 대하여 5 중량%인 것을 특징으로 하는 경피흡수제제.
- 제1항 내지 제5항 중 어느 한 항에 있어서, 상기 약물-함유 매트릭스층의 두께가 50 ㎛ 내지 100 ㎛의 범위인 것을 특징으로 하는 경피흡수제제.
- 제1항 내지 제5항 중 어느 한 항에 있어서, 상기 약물-함유 매트릭스층의 두께가 50 ㎛ 내지 80 ㎛의 범위인 것을 특징으로 하는 경피흡수제제.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201280009262.3A CN103429233B (zh) | 2011-02-18 | 2012-02-17 | 含有加兰他敏或其盐的经皮输送系统 |
EP12746904.7A EP2676663B1 (en) | 2011-02-18 | 2012-02-17 | Transdermal delivery system containing galantamine or salts thereof |
CA2827470A CA2827470A1 (en) | 2011-02-18 | 2012-02-17 | Transdermal delivery system containing galantamine or salts thereof |
JP2013554396A JP5883459B2 (ja) | 2011-02-18 | 2012-02-17 | ガランタミンまたはその塩を含む経皮送達システム |
AU2012218255A AU2012218255B2 (en) | 2011-02-18 | 2012-02-17 | Transdermal delivery system containing galantamine or salts thereof |
US13/985,994 US20130324950A1 (en) | 2011-02-18 | 2012-02-17 | Transdermal delivery system containing galantamine or salts thereof |
HK14101466.7A HK1189156A1 (zh) | 2011-02-18 | 2014-02-14 | 含有加蘭他敏或其鹽的經皮輸送系統 |
US15/215,302 US10758546B2 (en) | 2011-02-18 | 2016-07-20 | Transdermal delivery system containing galantamine or salts thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110014530A KR101317158B1 (ko) | 2011-02-18 | 2011-02-18 | 갈란타민 또는 그의 염을 함유하는 경피흡수제제 |
KR10-2011-0014530 | 2011-02-18 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/985,994 A-371-Of-International US20130324950A1 (en) | 2011-02-18 | 2012-02-17 | Transdermal delivery system containing galantamine or salts thereof |
US15/215,302 Continuation US10758546B2 (en) | 2011-02-18 | 2016-07-20 | Transdermal delivery system containing galantamine or salts thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012111996A2 true WO2012111996A2 (ko) | 2012-08-23 |
WO2012111996A3 WO2012111996A3 (ko) | 2012-10-26 |
Family
ID=46673057
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2012/001186 WO2012111996A2 (ko) | 2011-02-18 | 2012-02-17 | 갈란타민 또는 그의 염을 함유하는 경피흡수제제 |
Country Status (10)
Country | Link |
---|---|
US (2) | US20130324950A1 (ko) |
EP (1) | EP2676663B1 (ko) |
JP (1) | JP5883459B2 (ko) |
KR (1) | KR101317158B1 (ko) |
CN (1) | CN103429233B (ko) |
AU (1) | AU2012218255B2 (ko) |
CA (1) | CA2827470A1 (ko) |
HK (1) | HK1189156A1 (ko) |
MY (1) | MY166972A (ko) |
WO (1) | WO2012111996A2 (ko) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101317158B1 (ko) | 2011-02-18 | 2013-10-15 | 조선대학교산학협력단 | 갈란타민 또는 그의 염을 함유하는 경피흡수제제 |
JP6285820B2 (ja) * | 2014-08-07 | 2018-02-28 | 久光製薬株式会社 | ガランタミン含有経皮吸収製剤 |
US20180008612A1 (en) * | 2016-07-11 | 2018-01-11 | Taho Pharmaceuticals Ltd. | Transdermal delivery system containing galantamine or salts thereof |
CN106265678B (zh) * | 2016-07-18 | 2019-06-04 | 陕西省中医医院 | 一种用于治疗面瘫的膏药及其制备方法 |
DE102017115701B4 (de) * | 2017-07-12 | 2022-03-03 | Lts Lohmann Therapie-Systeme Ag | Fampridin-TTS |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5700480A (en) | 1993-01-23 | 1997-12-23 | Lts Lohman Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system comprising galanthamine as active component |
US20070104771A1 (en) | 2005-09-23 | 2007-05-10 | Jay Audett | Transdermal galantamine delivery system |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3843239C1 (ko) * | 1988-12-22 | 1990-02-22 | Lohmann Therapie Syst Lts | |
DE4010079A1 (de) * | 1990-03-29 | 1991-10-02 | Lohmann Therapie Syst Lts | Pharmazeutische formulierung zur behandlung des alkoholismus |
DE19527925C2 (de) * | 1995-07-29 | 1997-07-03 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit einer trennmittelbeschichteten Schutzschicht |
DE19906977C1 (de) * | 1999-02-19 | 2000-06-15 | Lohmann Therapie Syst Lts | Desoxypeganin-TTS und seine Verwendung |
US20050074487A1 (en) * | 1999-12-16 | 2005-04-07 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
JP4394443B2 (ja) * | 2001-10-17 | 2010-01-06 | 久光製薬株式会社 | 経皮吸収型製剤 |
EP2316437B1 (en) * | 2005-05-13 | 2014-07-30 | Alza Corporation | Multilayer drug delivery system with barrier against reservoir material flow |
TWI261378B (en) | 2005-09-19 | 2006-09-01 | Ind Tech Res Inst | Polarized light emitting device |
WO2007035939A2 (en) | 2005-09-23 | 2007-03-29 | Alza Corporation | High enhancer-loading polyacrylate formulation for transdermal applications |
TWI389709B (zh) * | 2005-12-01 | 2013-03-21 | Novartis Ag | 經皮治療系統 |
MY149152A (en) * | 2006-05-08 | 2013-07-15 | Teikoku Seiyaku Kk | Percutaneous absorption preparations of antimentia drugs |
JP5097359B2 (ja) * | 2006-05-09 | 2012-12-12 | 久光製薬株式会社 | ドネペジル経皮吸収型製剤 |
US8715715B2 (en) | 2008-11-03 | 2014-05-06 | Nal Pharmaceuticals Ltd. | Dosage form for insertion into the mouth |
CN102753158A (zh) * | 2009-12-16 | 2012-10-24 | 后藤武 | 抗痴呆药物的经皮吸收制剂 |
NZ605352A (en) | 2010-06-30 | 2013-10-25 | Nal Pharmaceuticals Ltd | Process for producing glycosaminoglycans |
KR101317158B1 (ko) | 2011-02-18 | 2013-10-15 | 조선대학교산학협력단 | 갈란타민 또는 그의 염을 함유하는 경피흡수제제 |
-
2011
- 2011-02-18 KR KR1020110014530A patent/KR101317158B1/ko active IP Right Grant
-
2012
- 2012-02-17 CA CA2827470A patent/CA2827470A1/en not_active Abandoned
- 2012-02-17 JP JP2013554396A patent/JP5883459B2/ja not_active Expired - Fee Related
- 2012-02-17 WO PCT/KR2012/001186 patent/WO2012111996A2/ko active Application Filing
- 2012-02-17 AU AU2012218255A patent/AU2012218255B2/en not_active Ceased
- 2012-02-17 MY MYPI2013003008A patent/MY166972A/en unknown
- 2012-02-17 EP EP12746904.7A patent/EP2676663B1/en not_active Not-in-force
- 2012-02-17 US US13/985,994 patent/US20130324950A1/en not_active Abandoned
- 2012-02-17 CN CN201280009262.3A patent/CN103429233B/zh not_active Expired - Fee Related
-
2014
- 2014-02-14 HK HK14101466.7A patent/HK1189156A1/zh not_active IP Right Cessation
-
2016
- 2016-07-20 US US15/215,302 patent/US10758546B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5700480A (en) | 1993-01-23 | 1997-12-23 | Lts Lohman Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system comprising galanthamine as active component |
US20070104771A1 (en) | 2005-09-23 | 2007-05-10 | Jay Audett | Transdermal galantamine delivery system |
Non-Patent Citations (16)
Title |
---|
ANG, C.; FEN, H.E.; SUB, H.E.: "Pharmacokinetics of galantamine Hbr in plasma and brain of mice", CHIN. J. PHARM, vol. 37, 2006, pages 55 - 61 |
CHOI, H-K.; ANGELLO, J.: "The Mathematical analysis and optimization of a flow through diffusion cell system", PHARM. RES, vol. 11, 1994, pages 595 - 599 |
COREY-BLOOM, J: "Galantamine: a review of its use in Alzheimer's disease and vascular dementia", INT. J. CLIN. PRACT, vol. 57, 2003, pages 219 - 223, XP008050022 |
COYLE, J.; KERSHAW, P.: "Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimers disease", BIOL. PSYCHIATRY, vol. 49, 2001, pages 289 - 299, XP001098881, DOI: doi:10.1016/S0006-3223(00)01101-X |
FURUISHI, T.; LO, T.; FUKAMI, T.; SUZUKI, T.; TOMONO, K.: "Formulation and in vitro evaluation of pentazocine transdermal delivery system", BIOL. PHARM. BULL, vol. 31, 2008, pages 1439 - 1443 |
KIM, J.H.; CHO Y.-J.; CHOI, H.-K.: "Effect of vehicles and pressure sensitive adhesives on the permeation of tacrine across hairless mouse skin", INT. J. PHARM, vol. 196, 2000, pages 105 - 113, XP000998581, DOI: doi:10.1016/S0378-5173(99)00449-4 |
MORIMOTO, Y.; KOKUBO, T.; SUGIBAYASHI, K.: "Diffusion of drug in acrylic type pressure sensitive adhesive matrix. II. Influence of interaction", J. CONTROL. RELEASE, vol. 18, 1992, pages 113 - 121, XP000247008, DOI: doi:10.1016/0168-3659(92)90180-Y |
SCOTT, L.J.; GOA, K.L.: "Galantamine: a review of its use in Alzheimer's disease", DRUGS, vol. 60, 2000, pages 1095 - 1122, XP009056233, DOI: doi:10.2165/00003495-200060050-00008 |
See also references of EP2676663A4 |
SUBEDI, R.K.; JANG, J.H.; KIM, JAE-II; PARK, Y.J.; CHOI, H.-K.: "Formulation and evaluation of transdermal patch containing sibutramine", J. KOR. PHARM. SCI, vol. 40, 2010, pages 33 - 38 |
SUBEDI, R.K.; JANG, J.H.; KIM, JAE-II; PARK, Y.J; CHOI, H.-K.: "Formulation and evaluation of transdermal patch containing sibutramine", J. KOR. PHARM. SCI, vol. 40, 2010, pages 33 - 38 |
THOMAS, B.J.; FINNIN, F.C.: "The transdermal revolution", DRUG DISCOV, vol. 9, 2004, pages 697 - 703 |
WALTERS, K.A.; WALKER, M.; OLEJNIK, O.: "Non-ionic surfactant effects on hairless mouse skin permeability characteristics", J. PHARM. PHARMACOL, vol. 40, 1987, pages 525 - 529 |
WILLIAMS, A.C.; BARRY, B.W.: "Permeation enhancers", ADV. DRUG DELIVER. REV, vol. 56, 2004, pages 603 - 618 |
WOKOVICH, A.M.; PRODDUTURI, S.; DOUB, W.H.; HUSSAIN, A.S.; BUHSE, L.F.: "Transdermal delivery system (TDDS) adhesion as a critical safety, efficacy and quality attribute", EUR. J. PHARM. BIOPHARM, vol. 64, 2006, pages 1 - 8, XP027997908, DOI: doi:10.1016/j.ejpb.2006.03.009 |
ZAROTSKY, V.; SRAMEK, J.J.; CUTLER, N.R.: "Galantamine hydrobromide: an agent for Alzheimer's disease", AM. J. HEALTH-SYST. PHARM, vol. 60, 2001, pages 446 - 452 |
Also Published As
Publication number | Publication date |
---|---|
EP2676663A2 (en) | 2013-12-25 |
CN103429233B (zh) | 2016-03-02 |
AU2012218255A1 (en) | 2013-09-12 |
CN103429233A (zh) | 2013-12-04 |
CA2827470A1 (en) | 2012-08-23 |
JP5883459B2 (ja) | 2016-03-15 |
KR101317158B1 (ko) | 2013-10-15 |
AU2012218255B2 (en) | 2017-01-19 |
JP2014505724A (ja) | 2014-03-06 |
US20130324950A1 (en) | 2013-12-05 |
US10758546B2 (en) | 2020-09-01 |
HK1189156A1 (zh) | 2014-05-30 |
KR20120106906A (ko) | 2012-09-27 |
EP2676663A4 (en) | 2015-06-03 |
EP2676663B1 (en) | 2018-05-23 |
US20160339038A1 (en) | 2016-11-24 |
WO2012111996A3 (ko) | 2012-10-26 |
MY166972A (en) | 2018-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8246979B2 (en) | Transdermal delivery system for the administration of rotigotine | |
US9295655B2 (en) | Fentanyl transdermal patch | |
US8246980B2 (en) | Transdermal delivery system | |
JP5190358B2 (ja) | 経皮吸収型製剤 | |
US20070264319A1 (en) | Transdermal Antiemesis Delivery System, Method and Composition Therefor | |
WO2012002640A2 (ko) | 도네페질을 함유하는 경피흡수제제 | |
AU2017384392B2 (en) | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene | |
WO2014195352A1 (en) | Transdermal delivery system | |
US10758546B2 (en) | Transdermal delivery system containing galantamine or salts thereof | |
US20090264806A1 (en) | Transdermal drug administration device | |
WO2006080199A1 (ja) | 貼付剤 | |
AU782487B2 (en) | Transdermal therapeutic system for the delivery of lerisetron | |
US20070202156A1 (en) | Adhesive preparation comprising sufentanil and methods of using same | |
KR102499141B1 (ko) | 수면장애 치료용 경피흡수제제 | |
US20050232983A1 (en) | Transdermal patch | |
AU2021256454A1 (en) | Transdermal and/or topical delivery system comprising hydroxychloroquine and/or chloroquine | |
US20140370077A1 (en) | Transdermal drug delivery system containing fentanyl | |
CN110913912A (zh) | 不可再贴的贴剂 | |
KR100623077B1 (ko) | 에스(+)-이부프로펜을 함유하는 경피투여용 조성물 및이를 함유하는 경피투여용 패취제 | |
WO2015072683A1 (ko) | 셀레질린 또는 그의 약학적으로 허용가능한 염을 함유하는 경피흡수제제 | |
US20210251916A1 (en) | Transdermal therapeutic system containing rivastigmine | |
KR101964295B1 (ko) | 피부 자극이 감소된 메만틴 경피전달 시스템 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12746904 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2827470 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2013554396 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13985994 Country of ref document: US Ref document number: 2012746904 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2012218255 Country of ref document: AU Date of ref document: 20120217 Kind code of ref document: A |